Top

BMC Cancer

Published in:

01-12-2020 | Glioma | Research article

Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis

Authors: Ruonan Jiao, Wei Jiang, Xin Wei, Mengpei Zhang, Si Zhao, Guangming Huang

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

Recent studies have highlighted the important role of long non-coding RNA SNHG16 in various human cancers. Here, we conducted a meta-analysis to investigate the effect of SNHG16 expression on clinicopathological features and prognosis in patients with different kinds of human cancers.

Methods

We performed a systematic search in electronic databases including PubMed, EMBASE, Cochrane Library and Web of Science, to investigate the potential association between SNHG16 expression and prognostic significance and clinical features in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were pooled to estimate the prognosis value of SNHG16 by StataSE 15.0 software.

Results

A total of 16 eligible studies with 1299 patients were enrolled in our meta-analysis. The results revealed that increased expression level of SNHG16 was significantly associated with larger tumor size (OR: 3.357; 95% CI: 2.173–5.185; P < 0.001), advanced TNM stage (OR: 2.930; 95% CI: 1.522–5.640; P = 0.001) and poor histological grade (OR: 3.943; 95% CI: 1.955–7.952; P < 0.001), but not correlated with smoking status (P = 0.489), sex (P = 0.932), distant metastasis (P = 0.052), or lymph node metastasis (P = 0.155). Moreover, the pooled HR showed that elevated expression SNHG16 was associated with a significantly poorer overall survival (OS) (HR = 1.866, 95% CI: 1.571–2.216, P < 0.001). For the set of cancer types, high expression of SNHG16 was significantly associated with shorter OS in patients with cancers of the urinary system (HR: 2.523, 95% CI:1.540–4.133; P <0.001), digestive system (HR: 2.406, 95% CI:1.556–3.721; P <0.001), and other cancers (including glioma and non-small cell lung cancer) (HR: 1.786, 95% CI:1.406–2.267; P <0.001).

Conclusions

LncRNA SNHG16 overexpression might serve as an unfavorable prognostic factor, which provides a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262 Torre, L. A.CrossRefPubMed

Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: the CRISPR generation. Eur J Cancer. 2018;93:10–8. https://doi.org/10.1016/j.ejca.2018.01.002.CrossRefPubMed

Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 2016;164(1–2):69–80. https://doi.org/10.1016/j.cell.2015.12.017.CrossRefPubMed

Yu WD, Wang H, He QF, Xu Y, Wang XC. Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 2018;233(9):6518–23. https://doi.org/10.1002/jcp.26568.CrossRefPubMed

Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100. https://doi.org/10.1111/cas.13642.CrossRefPubMedPubMedCentral

Xu T, Lin CM, Cheng SQ, Min J, Li L, Meng XM, Huang C, Zhang L, Deng ZY, Li J. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star. Mol Cancer. 2018;17(1):103. https://doi.org/10.1186/s12943-018-0852-7.CrossRefPubMedPubMedCentral

Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L, Xiong F, Zhang S, Gong Z, Nie S, et al. LncRNAs regulate the cytoskeleton and related rho/ROCK signaling in cancer metastasis. Mol Cancer. 2018;17(1):77. https://doi.org/10.1186/s12943-018-0825-x.CrossRefPubMedPubMedCentral

Sun C, Huang L, Li Z, Leng K, Xu Y, Jiang X, Cui Y. Long non-coding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci. 2018;25(1):23. https://doi.org/10.1186/s12929-018-0427-3.CrossRefPubMedPubMedCentral

Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, et al. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10(8):1266–82. https://doi.org/10.1016/j.molonc.2016.06.003.CrossRefPubMedPubMedCentral

10.

Cao X, Xu J, Yue D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Ther. 2018;25(1–2):10–7. https://doi.org/10.1038/s41417-017-0006-x.CrossRefPubMed

11.

Peng H, Li H. The encouraging role of long noncoding RNA small nuclear RNA host gene 16 in epithelial-mesenchymal transition of bladder cancer via directly acting on miR-17-5p/metalloproteinases 3 axis. Mol Carcinog. 2019;58(8):1465–80. https://doi.org/10.1002/mc.23028.CrossRefPubMed

12.

Zhu H, Zeng Y, Zhou CC, Ye W. SNHG16/miR-216-5p/ZEB1 signal pathway contributes to the tumorigenesis of cervical cancer cells. Arch Biochem Biophys. 2018;637:1–8. https://doi.org/10.1016/j.abb.2017.11.003.CrossRefPubMed

13.

Li Y, Lu Y, Chen Y. Long non-coding RNA SNHG16 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer via sponging miR-200a-3p. Biosci Rep. 2019;39(5):BSR20182498. https://doi.org/10.1042/BSR20182498.CrossRefPubMedPubMedCentral

14.

Han GH, Lu KJ, Wang P, Ye J, Ye YY, Huang JX. LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(12):3795–803. https://doi.org/10.26355/eurrev_201806_15262.CrossRefPubMed

15.

Wang X, Kan J, Han J, Zhang W, Bai L, Wu H. LncRNA SNHG16 functions as an oncogene by sponging MiR-135a and promotes JAK2/STAT3 signal pathway in gastric Cancer. J Cancer. 2019;10(4):1013–22. https://doi.org/10.7150/jca.29527.CrossRefPubMedPubMedCentral

16.

Lu YF, Cai XL, Li ZZ, Lv J, Xiang YA, Chen JJ, Chen WJ, Sun WY, Liu XM, Chen JB. LncRNA SNHG16 functions as an oncogene by sponging MiR-4518 and up-regulating PRMT5 expression in Glioma. Cell Physiol Biochem. 2018;45(5):1975–85. https://doi.org/10.1159/000487974.CrossRefPubMed

17.

Ye J, Zhang R, Du X, Chai W, Zhou Q. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p. Onco Targets Ther. 2019;12:415–22. https://doi.org/10.2147/OTT.S175176.CrossRefPubMedPubMedCentral

18.

Guo Z, Zhang J, Fan L, Liu J, Yu H, Li X, Sun G. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Med Sci Monit. 2019;25:2079–86. https://doi.org/10.12659/MSM.915541.CrossRefPubMedPubMedCentral

19.

Lin Q, Zheng H, Xu J, Zhang F, Pan H. LncRNA SNHG16 aggravates tumorigenesis and development of hepatocellular carcinoma by sponging miR-4500 and targeting STAT3. J Cell Biochem. 2019;120:11604–15. https://doi.org/10.1002/jcb.28440.CrossRef

20.

Han W, Du X, Liu M, Wang J, Sun L, Li Y. Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer. Int J Biol Macromol. 2019;121:270–8. https://doi.org/10.1016/j.ijbiomac.2018.10.004.CrossRefPubMed

21.

Liao S, Xing S, Ma Y. LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma. Cancer Chemother Pharmacol. 2019;83(6):1065–74. https://doi.org/10.1007/s00280-019-03822-5.CrossRefPubMed

22.

Wang X, Hu K, Chao Y, Wang L. LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis. Biomed Pharmacother. 2019;114:108798. https://doi.org/10.1016/j.biopha.2019.108798.CrossRefPubMed

23.

Yang XS, Wang GX, Luo L. Long non-coding RNA SNHG16 promotes cell growth and metastasis in ovarian cancer. Eur Rev Med Pharmacol Sci. 2018;22(3):616–22. https://doi.org/10.26355/eurrev_201802_14284.CrossRefPubMed

24.

Liu S, Zhang W, Liu K, Liu Y. LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Biomed Pharmacother. 2019;114:108862. https://doi.org/10.1016/j.biopha.2019.108862.CrossRefPubMed

25.

Wen Q, Zhao L, Wang T, Lv N, Cheng X, Zhang G, Bai L. LncRNA SNHG16 drives proliferation and invasion of papillary thyroid cancer through modulation of miR-497. Onco Targets Ther. 2019;12:699–708. https://doi.org/10.2147/OTT.S186923.CrossRefPubMedPubMedCentral

26.

Li J, Gao C, Liu C, Zhou C, Ma X, Li H, Li J, Wang X, Qi L, Yao Y, et al. Four lncRNAs associated with breast cancer prognosis identified by coexpression network analysis. J Cell Physiol. 2019;234(8):14019–30. https://doi.org/10.1002/jcp.28089.CrossRefPubMed

27.

Yang TX, Jin X, Lan JP, Wang WS. Long non-coding RNA SNHG16 has tumor suppressing effect in acute lymphoblastic leukemia by inverse interaction on hsa-miR-124-3p. IUBMB Life. 2019;71(1):134–42. https://doi.org/10.1002/iub.1947.CrossRefPubMed

28.

Xu FF, Guoqing Zha GQ, Wu YP, Cai WL, Ao J. Overexpressing lncRNA SNHG16 inhibited HCC proliferation and chemoresistance by functionally sponging hsa-mir-93. Onco Targets Ther. 2018;11:8855–63. https://doi.org/10.2147/OTT.S182005.CrossRefPubMedPubMedCentral

29.

Yang M, Wei W. SNHG16: a novel long-non coding RNA in human cancers. Onco Targets Ther. 2019;12:11679–90. https://doi.org/10.2147/OTT.S231630.CrossRefPubMedPubMedCentral

30.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https://doi.org/10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral

31.

Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127(3):761–71. https://doi.org/10.1172/JCI84424.CrossRefPubMedPubMedCentral

32.

Chandra Gupta S, Nandan TY. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2017;140(9):1955–67. https://doi.org/10.1002/ijc.30546.CrossRefPubMed

33.

Maggie MB, Aaron MJ. Exploring the mechanisms behind long Noncoding RNAs and Cancer. Noncoding RNA Res. 2018;3(3):108–17. https://doi.org/10.1016/j.ncrna.2018.03.001.CrossRef

34.

Yuan L, Xu ZY, Ruan SM, Mo SW, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric Cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19(1):96. https://doi.org/10.1186/s12943-020-01219-0.CrossRefPubMedPubMedCentral

35.

Jin KT, Yao JY, Fang XL, Di H, Ma YY. Roles of lncRNAs in Cancer: focusing on angiogenesis. Life Sci. 2020;252:117647. https://doi.org/10.1016/j.lfs.2020.117647.CrossRefPubMed

36.

Wang YJ, Sun BS, Wen X, Hao D, Du D, He G, Jiang X. The roles of lncRNA in cutaneous squamous cell carcinoma. Front Oncol. 2020;10:158. https://doi.org/10.3389/fonc.2020.00158.CrossRefPubMedPubMedCentral

37.

Lian D, Amin B, Du D, Yan W. Enhanced expression of the long non-coding RNA SNHG16 contributes to gastric cancer progression and metastasis. Cancer Biomark. 2017;21(1):151–60. https://doi.org/10.3233/CBM-170462.CrossRefPubMed

38.

Zhou Z, Zhu Y, Gao G, Zhang Y. Long noncoding RNA SNHG16 targets miR-146a-5p/CCL5 to regulate LPS-induced WI-38 cell apoptosis and inflammation in acute pneumonia. Life Sci. 2019;228:189–97. https://doi.org/10.1016/j.lfs.2019.05.008.CrossRefPubMed

39.

Gong CY. Tang R, Nan W, Zhou KS4, Zhang HH. Role of SNHG16 in human cancers. Clin Chim Acta. 2020;503:175–80. https://doi.org/10.1016/j.cca.2019.12.023.CrossRefPubMed

40.

Chen H, Li M, Huang P. LncRNA SNHG16 promotes hepatocellular carcinoma proliferation, migration and invasion by regulating miR-186 expression. J Cancer. 2019;10(15):3571–81. https://doi.org/10.7150/jca.28428.CrossRefPubMedPubMedCentral

41.

Xu C, Hu C, Wang Y, Liu S. Long Noncoding RNA SNHG16 promotes human retinoblastoma progression via sponging miR-140-5p. Biomed Pharmacother. 2019;117:109153. https://doi.org/10.1016/j.biopha.2019.109153.CrossRefPubMed

Title: Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis
Authors: Ruonan Jiao
Wei Jiang
Xin Wei
Mengpei Zhang
Si Zhao
Guangming Huang
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Glioma
Metastasis
Glioma
Glioma
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07149-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)

Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors

OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer